<p>辉瑞（NYSE:PFE - 获取免费报告）在周二发布的一份研究报告中，瑞银集团将其目标股价从 28.00 美元下调至 24.00 美元，Benzinga 报道。该券商目前对这家生物制药公司的股票给予 “中性” 评级。瑞银集团的目标价意味着该公司股价有潜在的 10.37% 的上涨空间。</p>
<ul>
<li>2 只医疗保健股票值得关注，因为摩根大通提升了吉利德的评级</li>
</ul>
<p>辉瑞的股票曾受到其他几份研究报告的关注。汇丰全球研究在 3 月 10 日的研究报告中将辉瑞的股票评级提升至 “强力买入”。高盛集团在周二的研究报告中重申了 “中性” 评级，并将辉瑞的目标价下调至 25.00 美元（之前为 32.00 美元）。Truist Financial 在 12 月 18 日的研究报告中将辉瑞的目标价从 36.00 美元下调至 32.00 美元，并对该股票给予 “买入” 评级。美国银行在 12 月 10 日的报告中重申了 “中性” 评级，并将辉瑞的目标价设定为 29.00 美元。最后，花旗在 3 月 27 日的研究报告中重申了辉瑞的 “中性” 评级。一位股票研究分析师对该股票给予了卖出评级，八位分析师给予持有评级，六位给予买入评级，三位给予强力买入评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，平均目标价为 31.07 美元。</p>
<p><strong>获取我们对辉瑞的最新分析</strong></p>
<h2>辉瑞股价下跌 3.9%</h2>
<ul>
<li>维京治疗公司：GLP-1 制造商会在批准前被收购吗？</li>
</ul>
<p>在周二的午盘交易中，NYSE:PFE 的股票下跌 0.89 美元，报 21.75 美元。该公司共交易了 72,206,792 股股票，而其平均交易量为 47,080,777 股。该股票的市值为 1233.3 亿美元，市盈率为 15.42，市盈增长比率为 0.64，贝塔值为 0.67。辉瑞的 52 周低点为 21.44 美元，52 周高点为 31.54 美元。该公司的 50 日简单移动平均线为 25.79 美元，200 日简单移动平均线为 26.67 美元。该公司的债务与股本比率为 0.63，流动比率为 1.00，速动比率为 0.73。</p>
<p>辉瑞（NYSE:PFE - 获取免费报告）最近一次公布季度财报是在 2 月 4 日。该生物制药公司报告本季度每股收益为 0.63 美元，超出分析师一致预期的 0.48 美元，超出幅度为 0.15 美元。辉瑞的净利润率为 12.62%，股本回报率为 19.47%。该公司本季度的收入为 177.6 亿美元，而分析师预期为 172.6 亿美元。去年同期，该公司的每股收益为 0.10 美元。该公司本季度的收入同比增长 24.7%。整体来看，卖方分析师预测辉瑞在当前财年将实现 2.95 美元的每股收益。</p>
<h2>辉瑞的内部活动</h2>
<ul>
<li>这些股票的收益未达预期，但下季度将反弹</li>
</ul>
<p>在其他消息中，董事罗纳德·E·布莱洛克在 2 月 13 日的交易中购买了 19,457 股该公司的股票。这些股票的平均购买价格为每股 25.65 美元，总价值为 499,072.05 美元。交易完成后，该董事现在直接持有 27,707 股公司股票，价值约为 710,684.55 美元。这代表着其持股比例增加了 235.84%。该购买在向证券交易委员会的备案中披露，相关文件可通过此链接访问。内部人士持有该公司 0.06% 的股票。</p>
<h2>对辉瑞的对冲基金看法</h2>
<p>一些机构投资者最近调整了对该公司的持股。先锋集团在第四季度将其在辉瑞的持股增加了 0.4%。先锋集团目前持有辉瑞 518,535,151 股股票，价值 13,756,738,000 美元，在此期间又购买了 2,285,276 股。查尔斯·施瓦布投资管理公司在第四季度将其辉瑞股票持有量增加了 19.5%。查尔斯·施瓦布投资管理公司目前持有辉瑞 155,459,101 股股票，价值 4,124,330,000 美元，在上个季度又购买了 25,315,159 股。Geode Capital Management LLC 在第四季度将其在辉瑞的持股增加了 2.5%。Geode Capital Management LLC 目前持有辉瑞 120,589,782 股股票，价值 3,190,131,000 美元，在此期间又收购了 2,923,537 股。挪威银行在第四季度购买了辉瑞的新股份，价值约为 2,328,986,000 美元。最后，马萨诸塞金融服务公司在第四季度将其在辉瑞的持股增加了 7.5%。马萨诸塞金融服务公司目前持有辉瑞 76,502,238 股股票，价值 2,029,604,000 美元，在此期间又收购了 5,350,381 股。68.36% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于辉瑞</h2>
<p>（获取免费报告）</p>
<p>辉瑞公司在美国、欧洲及国际市场上发现、开发、生产、营销、分销和销售生物制药产品。该公司在多个治疗领域提供药物和疫苗，包括心血管代谢、偏头痛和女性健康，品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；在满足医疗需求的传染病领域，品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的预防和治疗，以及潜在的未来 mRNA 和抗病毒产品，品牌包括 Comirnaty 和 Paxlovid。</p>
<h2>精彩故事</h2>
<ul>
<li>我们更看好的五只股票超过辉瑞</li>
<li>投资者如何从盘后交易中获益</li>
<li>抗关税股票：三只具有巨大上涨潜力的大便宜货</li>
<li>什么是 MACD 指标以及如何在交易中使用它</li>
<li>高通股价下跌，但相对强弱指数（RSI）显示其严重超卖</li>
<li>经济报告在成功投资策略中的作用</li>
<li>特斯拉的首席牛市分析师下调目标价，但表示仍然值得买入</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在辉瑞吗？</h2>
<p>在考虑辉瑞之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而辉瑞并不在名单上。</p>
<p>虽然辉瑞目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得买入。</p>
<p>在这里查看这五只股票</p>

辉瑞

<p>瑞士银行集团已将辉瑞（NYSE:PFE）的目标价从 28.00 美元下调至 24.00 美元，维持 “中性” 评级。这一调整表明与前一交易日收盘价相比，潜在上涨幅度为 10.37%。其他分析师的看法各异，有的给予 “强烈买入” 评级，有的则维持中性或买入评级。辉瑞的股票最近下跌了 3.9%，报 21.75 美元，平均目标价为 31.07 美元。该公司报告了强劲的季度收益，收入达到 177.6 亿美元，超出预期</p>

<p>Pfizer (NYSE:PFE - Get Free Report) had its price objective reduced by stock analysts at UBS Group from $28.00 to $24.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has a &#34;neutral&#34; rating on the biopharmaceutical company's stock. UBS Group's price target points to a potential upside of 10.37% from the company's previous close.</p>
<div class="lb-trans"><p>辉瑞（NYSE:PFE - 获取免费报告）在周二发布的一份研究报告中，瑞银集团将其目标股价从 28.00 美元下调至 24.00 美元，Benzinga 报道。该券商目前对这家生物制药公司的股票给予 “中性” 评级。瑞银集团的目标价意味着该公司股价有潜在的 10.37% 的上涨空间。</p>
</div><ul>
<li>2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只医疗保健股票值得关注，因为摩根大通提升了吉利德的评级</li>
</ul>
</div><p>PFE has been the subject of several other research reports. Hsbc Global Res raised shares of Pfizer to a &#34;strong-buy&#34; rating in a research note on Monday, March 10th. The Goldman Sachs Group reissued a &#34;neutral&#34; rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research report on Tuesday. Truist Financial cut their price objective on Pfizer from $36.00 to $32.00 and set a &#34;buy&#34; rating on the stock in a research report on Wednesday, December 18th. Bank of America reiterated a &#34;neutral&#34; rating and issued a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Finally, Citigroup reissued a &#34;neutral&#34; rating on shares of Pfizer in a research note on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $31.07.</p>
<div class="lb-trans"><p>辉瑞的股票曾受到其他几份研究报告的关注。汇丰全球研究在 3 月 10 日的研究报告中将辉瑞的股票评级提升至 “强力买入”。高盛集团在周二的研究报告中重申了 “中性” 评级，并将辉瑞的目标价下调至 25.00 美元（之前为 32.00 美元）。Truist Financial 在 12 月 18 日的研究报告中将辉瑞的目标价从 36.00 美元下调至 32.00 美元，并对该股票给予 “买入” 评级。美国银行在 12 月 10 日的报告中重申了 “中性” 评级，并将辉瑞的目标价设定为 29.00 美元。最后，花旗在 3 月 27 日的研究报告中重申了辉瑞的 “中性” 评级。一位股票研究分析师对该股票给予了卖出评级，八位分析师给予持有评级，六位给予买入评级，三位给予强力买入评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，平均目标价为 31.07 美元。</p>
</div><p><strong>Get Our Latest Analysis on PFE</strong></p>
<div class="lb-trans"><p><strong>获取我们对辉瑞的最新分析</strong></p>
</div><h2>Pfizer Trading Down 3.9 %</h2>
<div class="lb-trans"><h2>辉瑞股价下跌 3.9%</h2>
</div><ul>
<li>Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?</li>
</ul>
<div class="lb-trans"><ul>
<li>维京治疗公司：GLP-1 制造商会在批准前被收购吗？</li>
</ul>
</div><p>Shares of NYSE:PFE traded down $0.89 during midday trading on Tuesday, reaching $21.75. 72,206,792 shares of the company's stock were exchanged, compared to its average volume of 47,080,777. The stock has a market cap of $123.33 billion, a price-to-earnings ratio of 15.42, a P/E/G ratio of 0.64 and a beta of 0.67. Pfizer has a fifty-two week low of $21.44 and a fifty-two week high of $31.54. The firm's 50 day simple moving average is $25.79 and its two-hundred day simple moving average is $26.67. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.</p>
<div class="lb-trans"><p>在周二的午盘交易中，NYSE:PFE 的股票下跌 0.89 美元，报 21.75 美元。该公司共交易了 72,206,792 股股票，而其平均交易量为 47,080,777 股。该股票的市值为 1233.3 亿美元，市盈率为 15.42，市盈增长比率为 0.64，贝塔值为 0.67。辉瑞的 52 周低点为 21.44 美元，52 周高点为 31.54 美元。该公司的 50 日简单移动平均线为 25.79 美元，200 日简单移动平均线为 26.67 美元。该公司的债务与股本比率为 0.63，流动比率为 1.00，速动比率为 0.73。</p>
</div><p>Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. During the same period last year, the business earned $0.10 earnings per share. The business's revenue for the quarter was up 24.7% on a year-over-year basis. As a group, sell-side analysts forecast that Pfizer will post 2.95 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>辉瑞（NYSE:PFE - 获取免费报告）最近一次公布季度财报是在 2 月 4 日。该生物制药公司报告本季度每股收益为 0.63 美元，超出分析师一致预期的 0.48 美元，超出幅度为 0.15 美元。辉瑞的净利润率为 12.62%，股本回报率为 19.47%。该公司本季度的收入为 177.6 亿美元，而分析师预期为 172.6 亿美元。去年同期，该公司的每股收益为 0.10 美元。该公司本季度的收入同比增长 24.7%。整体来看，卖方分析师预测辉瑞在当前财年将实现 2.95 美元的每股收益。</p>
</div><h2>Insider Activity at Pfizer</h2>
<div class="lb-trans"><h2>辉瑞的内部活动</h2>
</div><ul>
<li>These Stocks Missed on Earnings, But Will Rebound Next Quarter</li>
</ul>
<div class="lb-trans"><ul>
<li>这些股票的收益未达预期，但下季度将反弹</li>
</ul>
</div><p>In other news, Director Ronald E. Blaylock purchased 19,457 shares of the business's stock in a transaction on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Insiders own 0.06% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，董事罗纳德·E·布莱洛克在 2 月 13 日的交易中购买了 19,457 股该公司的股票。这些股票的平均购买价格为每股 25.65 美元，总价值为 499,072.05 美元。交易完成后，该董事现在直接持有 27,707 股公司股票，价值约为 710,684.55 美元。这代表着其持股比例增加了 235.84%。该购买在向证券交易委员会的备案中披露，相关文件可通过此链接访问。内部人士持有该公司 0.06% 的股票。</p>
</div><h2>Hedge Funds Weigh In On Pfizer</h2>
<div class="lb-trans"><h2>对辉瑞的对冲基金看法</h2>
</div><p>A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. increased its stake in Pfizer by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company's stock valued at $13,756,738,000 after purchasing an additional 2,285,276 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of Pfizer by 19.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock worth $4,124,330,000 after buying an additional 25,315,159 shares during the last quarter. Geode Capital Management LLC increased its position in Pfizer by 2.5% in the 4th quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company's stock valued at $3,190,131,000 after acquiring an additional 2,923,537 shares during the period. Norges Bank purchased a new stake in Pfizer during the 4th quarter valued at approximately $2,328,986,000. Finally, Massachusetts Financial Services Co. MA lifted its position in Pfizer by 7.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock worth $2,029,604,000 after acquiring an additional 5,350,381 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些机构投资者最近调整了对该公司的持股。先锋集团在第四季度将其在辉瑞的持股增加了 0.4%。先锋集团目前持有辉瑞 518,535,151 股股票，价值 13,756,738,000 美元，在此期间又购买了 2,285,276 股。查尔斯·施瓦布投资管理公司在第四季度将其辉瑞股票持有量增加了 19.5%。查尔斯·施瓦布投资管理公司目前持有辉瑞 155,459,101 股股票，价值 4,124,330,000 美元，在上个季度又购买了 25,315,159 股。Geode Capital Management LLC 在第四季度将其在辉瑞的持股增加了 2.5%。Geode Capital Management LLC 目前持有辉瑞 120,589,782 股股票，价值 3,190,131,000 美元，在此期间又收购了 2,923,537 股。挪威银行在第四季度购买了辉瑞的新股份，价值约为 2,328,986,000 美元。最后，马萨诸塞金融服务公司在第四季度将其在辉瑞的持股增加了 7.5%。马萨诸塞金融服务公司目前持有辉瑞 76,502,238 股股票，价值 2,029,604,000 美元，在此期间又收购了 5,350,381 股。68.36% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Pfizer</h2>
<div class="lb-trans"><h2>关于辉瑞</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p>
<div class="lb-trans"><p>辉瑞公司在美国、欧洲及国际市场上发现、开发、生产、营销、分销和销售生物制药产品。该公司在多个治疗领域提供药物和疫苗，包括心血管代谢、偏头痛和女性健康，品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；在满足医疗需求的传染病领域，品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的预防和治疗，以及潜在的未来 mRNA 和抗病毒产品，品牌包括 Comirnaty 和 Paxlovid。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精彩故事</h2>
</div><ul>
<li>Five stocks we like better than Pfizer</li>
<li>How Can Investors Benefit From After-Hours Trading</li>
<li>Tariff-Proof Stocks: 3 Big Bargains With Huge Upside Potential</li>
<li>What is the MACD Indicator and How to Use it in Your Trading</li>
<li>Qualcomm Breaks Down But RSI Signals It’s Severely Oversold</li>
<li>The Role Economic Reports Play in a Successful Investment Strategy</li>
<li>Tesla’s #1 Bull Cuts Target But Says It’s Still a Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过辉瑞</li>
<li>投资者如何从盘后交易中获益</li>
<li>抗关税股票：三只具有巨大上涨潜力的大便宜货</li>
<li>什么是 MACD 指标以及如何在交易中使用它</li>
<li>高通股价下跌，但相对强弱指数（RSI）显示其严重超卖</li>
<li>经济报告在成功投资策略中的作用</li>
<li>特斯拉的首席牛市分析师下调目标价，但表示仍然值得买入</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=PFE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Pfizer Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在辉瑞吗？</h2>
</div><p>Before you consider Pfizer, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑辉瑞之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而辉瑞并不在名单上。</p>
</div><p>While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然辉瑞目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得买入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Pfizer (NYSE:PFE) Price Target Cut to $24.00 by Analysts at UBS Group

- UBS 将辉瑞的目标价从 $28.00 下调至 $24.00，维持 “中性” 评级。  
- 辉瑞股价下跌 3.9%，最新交易价为 $21.75，市值为 $1233.3 亿美元。  
- 辉瑞最新季度每股收益为 $0.63，超出预期，营收同比增长 24.7%。  

瑞银集团的分析师将辉瑞（纽约证券交易所代码：PFE）的目标价下调至 24.00 美元